Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.
1. A method of treating cystic fibrosis in a mammal comprising administering to the mammal an effective amount of 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, characterized as Form I, and an additional therapeutic agent.
2. The method of claim 1 , wherein the additional therapeutic agent is a mucolytic agent, a bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator, or a nutritional agent.
3. The method of claim 1 , wherein the mammal has a defective gene that causes a deletion of phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator (CFTR) amino acid sequence.
4. The method of claim 3 , wherein the mammal has two copies of the defective gene.
5. A method of treating cystic fibrosis in a mammal comprising administering to the mammal an effective amount of: (a) 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, characterized as Form I, wherein the Form I is characterized by one or more peaks within one or more 2θ ranges selected from 15.2 to 15.6, 16.1 to 16.5, and 14.3 to 14.7 degrees in an X-ray powder diffraction pattern obtained using Cu K alpha radiation at 40 kV, 35 mA; and (b) an additional therapeutic agent.
6. The method of claim 5 , wherein the Form I is characterized by a peak within the range of 15.2 to 15.6 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
7. The method of claim 6 , wherein the Form I is characterized by a peak at 15.4 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
8. The method of claim 5 , wherein the Form I is characterized by a peak within the range of 16.1 to 16.5 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
9. The method of claim 8 , wherein the Form I is characterized by a peak at 16.3 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
10. The method of claim 5 , wherein the Form I is characterized by a peak within the range of 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
11. The method of claim 10 , wherein the Form I is characterized by a peak at 14.5 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
12. The method of claim 5 , wherein the Form I is further characterized by a peak within the range of 17.6 to 18.0 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
13. The method of claim 5 , wherein Compound 1 Form I is further characterized by a peak within the range of 7.6 to 8.0 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
14. The method of claim 5 , wherein the Form I is characterized by one or more peaks having a 2θ value, ± 0 . 2 degrees, selected from 14.41 degrees, 14.64 degrees, 15.23 degrees, 16.11 degrees, 17.67 degrees, 19.32 degrees, 21.67 degrees, 23.40 degrees, 23.99 degrees, 26.10 degrees, and 28.54 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
15. The method of claim 5 , wherein the Form I is characterized by one or more peaks having a 2θ value, ±0.2 degrees, selected from 7.83 degrees, 14.51 degrees, 14.78 degrees, 15.39 degrees, 16.26 degrees, 16.62 degrees, 17.81 degrees, 21.59 degrees, 23.32 degrees, 24.93 degrees, and 25.99 degrees, in an X-ray powder diffraction obtained using Cu K alpha radiation.
16. The method of claim 1 , wherein the Form I is characterized by a diffraction pattern substantially similar to that of FIG. 1 .
17. The method of claim 1 , wherein the Form I is characterized by a diffraction pattern substantially similar to that of FIG. 2 .
18. A method of treating cystic fibrosis in a mammal comprising administering to the mammal an effective amount of: (a) 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, characterized as Form I, wherein the Form I is characterized as a monoclinic crystal system in P 2 i /n space group with the following unit cell dimensions:
a=4.9626 (7) Å α=90°
b=12.2994 (18) Å β=93.938 (9)°
c=33.075 (4) Å γ=90°.